Showing 1 posts of 1 posts found.
Regenxbio has announced topline results from the phase 1/2/3 CAMPSIITE trial of RGX-121 for the treatment of patients up to …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion